Aclarion (ACON) Stock Price, News & Analysis

Company Overview

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Key Stats

• Today's Range: $2.64 to $2.86
• 50-Day Range: $2.71 to $3.73
• 52-Week Range: $2.34 to $12.03
• Volume: 40,792 shs
• Average Volume: 83,595 shs
• Market Capitalization: $7.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Hold

Aclarion Stock Analysis - MarketRank™

Aclarion scored higher than 73% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Aclarion has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Aclarion has a consensus price target of $7.50, representing about 163.2% upside from its current price of $2.85.

Amount of Analyst Coverage

Aclarion has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aclarion are expected to decrease in the coming year, from ($4.51) to ($5.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aclarion is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aclarion is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aclarion has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.12% of the float of Aclarion has been sold short.

Short Interest Ratio / Days to Cover

Aclarion has a short interest ratio ("days to cover") of 2.59, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aclarion has recently decreased by 29.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aclarion does not currently pay a dividend.

Dividend Growth

Aclarion does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: N/A

News Sentiment

Aclarion has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Aclarion this week, compared to 3 articles on an average week.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of Aclarion in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $50,915.00 in company stock, which represents 0.7262% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Aclarion insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,915.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.01% of the stock of Aclarion is held by insiders.

Percentage Held by Institutions

7.52% of the stock of Aclarion is held by institutions.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 6/26/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:ACON
• CIK: 1635077
• Web: www.aclarion.com
• Phone: 833-275-2266
• Fax: N/A
• Employees: 7
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Aclarion: $7.50
• High Price Target: $7.50
• Low Price Target: $7.50
• Potential Upside/Downside: +163.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.23 million
• Net Margins: -10,320.51%
• Pretax Margin: -10,321.80%
• Return on Equity: -54.41%
• Return on Assets: -51.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.65
• Quick Ratio: 19.65

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 87.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.02 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 2,460,000
• Free Float: 2,462,000
• Market Cap: $7.01 million
• Optionable: Not Optionable
• Beta: 1.22